BMG Pharma holds 206 patents, filed or registered in various geographical areas worldwide, divided into 12 patent families, 9 of which concern Hyaluromimethic® technology and new biomaterials derived from the chemical modification of hyaluronic acid.

This technology platform is at the core of the company's development strategy, on which resources continue to be invested.

The remaining 3 patent families cover new ingredients or formulation combinations and processes for the protection of technologies dedicated to various therapeutic areas.

The patents were registered to safeguard the company's strategic processes, increaseing the guarantee of protection of the technologies and development processes of the new molecules developed by.